Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease
Article information
Abstract
Diabetic kidney disease (DKD) is a major contributor to chronic kidney disease (CKD) and end-stage kidney disease worldwide, and is strongly associated with increased cardiovascular morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for glycemic control, are now established as key therapies for DKD patients. Large, randomized clinical trials, including CREDENCE, DAPA-CKD, and EMPA-KIDNEY, have consistently shown that SGLT2 inhibitors reduce the risk of kidney disease progression, cardiovascular events, and hospitalization for heart failure in patients with and without diabetes. These benefits extend beyond lowering glucose and are attributed to multiple complementary mechanisms, including restoration of tubuloglomerular feedback, reduction of intraglomerular pressure, natriuresis, and pleiotropic effects, such as improved metabolic efficiency, attenuation of inflammation and fibrosis, and enhanced renal oxygenation. The management of DKD is increasingly shifting toward a combination-based strategy targeting diverse pathogenic pathways. Emerging data suggest that combining SGLT2 inhibitors with other cardiorenal protective agents, such as renin-angiotensin system inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide 1 receptor agonists, may provide additional benefits. Recent guidelines emphasize the use of SGLT2 inhibitors primarily for cardiorenal protection independent of glycemic control. Despite these advances, important gaps remain in underrepresented populations, including the elderly, non-albuminuric DKD, advanced CKD, kidney transplant recipients, and patients with type 1 diabetes. This review provides an overview of the key mechanisms and clinical evidence supporting the use of SGLT2 inhibitors in DKD, along with emerging insights into combination strategies and their clinical implications.
Introduction
The global prevalence of diabetes mellitus has markedly increased over the past few decades, creating a substantial burden on healthcare systems worldwide [1]. Diabetic kidney disease (DKD) is one of the most prevalent and clinically significant complications of diabetes, affecting approximately 30%–40% of patients [2]. DKD continues to be the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in many regions and is associated with a higher risk of cardiovascular morbidity and mortality [3–5].
Patients with DKD are at high risk of progressive kidney function decline, cardiovascular events, and premature death. For many years, therapeutic strategies to slow DKD progression have been limited to glycemic control, blood pressure management, and renin-angiotensin system (RAS) blockade. Although these approaches reduce albuminuria and delay the progression of kidney disease, substantial residual risk remains [5].
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally introduced for glycemic control, are now widely recognized as effective therapeutic options for patients with DKD [6]. Evidence from large randomized clinical trials (RCTs) has shown that SGLT2 inhibitors substantially lower the risk of kidney disease progression, cardiovascular events, hospitalization for heart failure, and mortality [7]. These benefits appear to extend beyond lowering glucose and involve multiple hemodynamic and metabolic mechanisms [8].
In this narrative review, we summarize the mechanisms underlying kidney protection by SGLT2 inhibitors and review major clinical trials evaluating their efficacy in DKD patients. We also discuss the emerging evidence surrounding combination therapy with other cardiorenal protective agents, current guideline recommendations, and considerations of their use in specific patient populations.
Mechanisms of kidney protection
SGLT2 inhibitors reduce glucose reabsorption in the proximal tubules by inhibiting SGLT2 transporters, thereby promoting glycosuria and natriuresis. Although initially introduced as anti-hyperglycemic agents, it has become clear that their kidney-protective effects extend beyond glucose-lowering and involve several complementary mechanisms (Fig. 1).
Mechanistic pathways of SGLT2 inhibitors beyond glucose-lowering in DKD patients.
This figure illustrates the key pleiotropic mechanisms underlying the kidney protective effects of SGLT2 inhibitors in DKD. SGLT2 inhibition in the proximal tubules reduces glucose and sodium reabsorption, leading to glycosuria and natriuresis. These primary effects trigger multiple downstream pathways, including metabolic, anti-inflammatory, anti-fibrotic, and oxygenation-related pathways. The metabolic effects involve a shift toward ketone body utilization and improved energy efficiency. Anti-inflammatory actions are mediated by a reduction in oxidative stress and pro-inflammatory cytokines. Anti-fibrotic effects are primarily driven by suppression of pro-fibrotic signaling pathways such as transforming growth factor beta (TGF-β). Improved oxygenation results from reduced tubular workload and oxygen demand, thereby alleviating tubulointerstitial hypoxia. These integrated mechanisms collectively contribute to the cardiorenal protective effects of SGLT2 inhibitors, which are largely independent of their glucose-lowering properties.
ATP, adenosine triphosphate; DKD, diabetic kidney disease; ECM, extracellular matrix; ICAM-1, intercellular adhesion molecule 1; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; NADPH, nicotinamide adenine dinucleotide phosphate; ROS, reactive oxygen species; SGLT2, sodium-glucose cotransporter 2; TNF-α, tumor necrosis factor alpha.
Restoration of tubuloglomerular feedback
In the diabetic state, an increased filtered glucose load promotes the augmented reabsorption of both glucose and sodium in the proximal tubules through SGLT2. Consequently, sodium delivery to the macula densa decreases, leading to impaired tubuloglomerular feedback and subsequent dilation of afferent arterioles. The consequent increase in intraglomerular pressure contributes to glomerular hyperfiltration and progressive kidney injury [9]. SGLT2 inhibitors enhance sodium delivery to the macula densa by inhibiting sodium reabsorption in the proximal tubules. This restores tubuloglomerular feedback, leading to afferent arteriolar vasoconstriction and reduction in intraglomerular pressure. As a result, SGLT2 inhibitors mitigate glomerular hyperfiltration and reduce mechanical stress on the glomerular filtration barrier [9]. This hemodynamic effect is similar in concept to the protective mechanism of RAS blockade but occurs through a distinct pathway. The early decline in the estimated glomerular filtration rate (eGFR) observed after the initiation of SGLT2 inhibitors is thought to reflect this reduction in intraglomerular pressure and is generally reversible [10].
Natriuresis and improved blood pressure control
SGLT2 inhibitors promote natriuresis and osmotic diuresis, contributing to modest reductions in blood pressure and plasma volume. These effects may improve cardiovascular hemodynamics and reduce kidney congestion, particularly in patients with heart failure [11].
Metabolic effects
In addition to lowering glucose levels, SGLT2 inhibitors induce modest weight loss and improve insulin sensitivity by sustaining glycosuria and calorie loss. This results in increased lipolysis and a metabolic shift toward fatty acid oxidation and ketone body production. Reduced plasma glucose levels lead to decreased insulin secretion and a relative increase in glucagon levels, thereby increasing the glucagon-to-insulin ratio and promoting ketogenesis [12]. Ketone bodies may serve as energy-efficient substrates, generating more ATP per unit of oxygen than glucose or fatty acids, which may improve myocardial and renal energy efficiency [13].
Anti-inflammatory and antifibrotic effects
Experimental studies have suggested that SGLT2 inhibitors attenuate the key inflammatory and fibrotic pathways involved in DKD progression. These effects are mediated, in part, by a reduction in oxidative stress via the inhibition of NADPH oxidase activity, leading to decreased production of reactive oxygen species [14]. SGLT2 inhibitors have been shown to downregulate pro-inflammatory cytokines such as interleukin 6, tumor necrosis factor alpha, and monocyte chemoattractant protein 1, as well as adhesion molecules including intercellular adhesion molecule 1 [15]. Furthermore, they suppress transforming growth factor-β signaling, a central pathway in renal fibrosis, thereby reducing extracellular matrix accumulation and interstitial fibrosis [16]. In addition, these agents promote a shift toward anti-inflammatory M2 macrophage polarization and reduce macrophage infiltration into renal tissues, contributing to the attenuation of both inflammation and fibrosis [17].
Improved oxygenation
SGLT2 inhibitors may improve renal oxygenation by reducing the proximal tubular workload and enhancing metabolic efficiency. By inhibiting SGLT2-mediated sodium and glucose reabsorption, these agents decrease ATP consumption and oxygen demand in proximal tubular cells [18]. This may alleviate tubulointerstitial hypoxia, which is a key driver of inflammation and fibrosis in DKD [19]. Additionally, the restoration of mitochondrial function and reduction in oxidative stress may further contribute to improved renal oxygen handling [9].
Collectively, these hemodynamic, metabolic, and anti-inflammatory mechanisms contribute to the overall renoprotective effects of SGLT2 inhibitors in slowing kidney disease progression.
Evidence from randomized clinical trials
Evidence supporting the use of SGLT2 inhibitors in DKD has emerged from both cardiovascular and dedicated kidney outcome trials.
Cardiovascular outcome trials (secondary kidney outcomes)
Several large cardiovascular outcome trials evaluating SGLT2 inhibitors in patients with type 2 diabetes (T2D) have demonstrated important kidney benefits as secondary outcomes.
The EMPA-REG OUTCOME trial investigated the effects of empagliflozin in patients with T2D and established cardiovascular disease. Treatment with empagliflozin was associated with a significant reduction in the risk of incident or worsening nephropathy and a slower decline in kidney function compared to placebo [20]. Similarly, the CANVAS program assessed canagliflozin in patients with T2D at high cardiovascular risk. Canagliflozin treatment reduced the progression of albuminuria and slowed kidney function decline [21]. The DECLARE-TIMI 58 trial evaluated dapagliflozin in a broad population of patients with T2D and demonstrated a reduction in composite kidney outcomes, including a sustained decline in eGFR and the development of ESKD [22]. Although kidney outcomes were secondary endpoints in these trials, the consistent renoprotective effects observed across multiple studies provide strong evidence supporting the role of SGLT2 inhibitors in kidney protection.
Dedicated kidney outcome trials
Subsequent RCTs specifically designed to evaluate kidney outcomes confirmed the benefits of SGLT2 inhibitors in CKD (Table 1).
The CREDENCE trial was the first dedicated kidney outcome trial to evaluate SGLT2 inhibitors in patients with DKD. This study enrolled patients with T2D, albuminuric CKD, and an eGFR between 30 and 90 mL/min/1.73 m2 who were already receiving RAS blockade. Canagliflozin was associated with a significant reduction in the risk of the primary composite outcomes, including ESKD, doubling of serum creatinine levels, and renal or cardiovascular death. The trial demonstrated a relative risk reduction of approximately 30% in kidney outcomes and provided definitive evidence supporting the renoprotective effects of SGLT2 inhibitors in DKD patients [23].
The DAPA-CKD trial extended these findings by evaluating dapagliflozin in patients with CKD, with and without diabetes. This study enrolled patients with an eGFR ranging from 25 to 75 mL/min/1.73 m2 who had albuminuria. Dapagliflozin treatment was associated with a significant reduction in the risk of sustained eGFR decline, ESKD, or death from renal or cardiovascular causes. Importantly, the benefits were observed regardless of diabetes status, highlighting that the kidney-protective effects of SGLT2 inhibitors are not solely mediated by lowering glucose [24].
The EMPA-KIDNEY trial further broadened the evidence base by enrolling a wide range of CKD patients, including those with and without diabetes, with an eGFR of 20–45 mL/min/1.73 m2 regardless of albuminuria status, or an eGFR of 45–90 mL/min/1.73 m2 with a urine albumin-to-creatinine ratio ≥200 mg/g. Notably, this trial included patients with lower levels of albuminuria than those in previous studies, thereby expanding the generalizability of SGLT2 inhibitor therapy across a broader CKD population. Empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death compared to placebo [25].
These trials demonstrated a progressive expansion in the role of SGLT2 inhibitors from DKD (CREDENCE) to CKD regardless of diabetes (DAPA-CKD), and further to broader CKD populations, including those with lower albuminuria (EMPA-KIDNEY). A subsequent large-scale meta-analysis further confirmed that SGLT2 inhibitors consistently reduce the risk of CKD progression across a wide range of baseline kidney function and albuminuria levels, including in patients with advanced CKD and minimal albuminuria [26].
Notably, these benefits appear to be highly relevant to Asian populations, who are at increased risk of DKD and experience more rapid disease progression [27]. A meta-analysis of RCTs in Asian patients demonstrated that SGLT2 inhibitors attenuate kidney function decline, as reflected by a slower reduction in eGFR and improvements in renal biomarkers [28]. Furthermore, region-specific studies and expert consensus reports have confirmed that SGLT2 inhibitors effectively reduce albuminuria and slow kidney function decline in Asian patients with DKD [29]. These findings are further supported by nationwide Korean real-world data, in which SGLT2 inhibitor use was associated with a lower risk of composite kidney outcomes, acute kidney injury, and CKD compared with other glucose-lowering agents [30].
Combination therapy in the era of the “four pillars”
The management of DKD is evolving toward a strategy of combination therapy targeting multiple pathophysiological pathways. In addition to RAS blockade, several classes of agents have demonstrated cardiorenal protective effects, leading to the concept of “four-pillar therapy” (Fig. 2).
Conceptual framework of combination therapy in DKD.
This figure illustrates the conceptual framework of combination therapy for DKD, incorporating four major therapeutic pillars: renin-angiotensin system inhibitor (RASi), sodium-glucose cotransporter 2 inhibitor (SGLT2i), nonsteroidal mineralocorticoid receptor antagonist (nsMRA), and glucagon-like peptide-1 receptor agonist (GLP-1RA). Solid lines indicate combinations with evidence supporting additive or enhanced therapeutic effects, as demonstrated in randomized clinical trials (e.g., SGLT2i + nsMRA in the CONFIDENCE trial [34]). Dashed lines indicate combinations in which no attenuation of therapeutic efficacy was observed when used concomitantly in clinical trials or post hoc analyses, although dedicated randomized evidence remains limited.
DKD, diabetic kidney disease; RAAS, renin-angiotensin-aldosterone system.
RAS blockade with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers remains the foundational therapy for DKD. The major SGLT2 inhibitor trials were conducted in addition to background RAS blockade, demonstrating additive benefits when these therapies are used together [23–25]. Recent real-world data further suggest that the addition of SGLT2 inhibitors to ongoing RAS blockade may confer additional clinical advantages by reducing the risk of hyperkalemia and facilitating the continuation of RAS inhibitor therapy [31].
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has been shown to reduce kidney and cardiovascular outcomes in patients with DKD in the FIDELIO-DKD [32] and FIGARO-DKD trials [33]. Recent results from the CONFIDENCE trial showed that combination therapy with finerenone and empagliflozin led to greater reductions in albuminuria than monotherapy, suggesting additive renoprotective effects through complementary mechanisms [34]. Notably, a secondary analysis of the CONFIDENCE trial showed that the addition of empagliflozin to finerenone did not significantly reduce the risk of hyperkalemia compared with finerenone alone, despite its preserved efficacy [35].
Glucagon-like peptide 1 (GLP-1) receptor agonists provide cardiovascular benefits and kidney-protective effects, with the strongest evidence for semaglutide. The FLOW trial demonstrated that semaglutide significantly reduced the risk of kidney disease progression in patients with T2D and CKD [36]. Given their distinct mechanisms of action, SGLT2 inhibitors and GLP-1 receptor agonists may provide complementary cardiorenal protection. Indeed, emerging evidence from post hoc analyses suggests that combination therapy may offer additive cardiovascular and renal benefits [37,38]; however, dedicated RCTs evaluating this strategy are lacking.
As the therapeutic landscape continues to evolve, combination therapy with multiple cardioprotective agents is likely to become an increasingly important strategy for DKD patient management. Recent evidence from the acute kidney disease (AKD) setting further supports early and sequential use of multiple cardiorenal protective agents, highlighting the potential benefits of combination strategies even during the transition from AKD to CKD [39].
Current guideline recommendations
Recent clinical guidelines strongly support the use of SGLT2 inhibitors in patients with DKD. The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines recommend SGLT2 inhibitors for patients with T2D and CKD with an eGFR of at least 20 mL/min/1.73 m2. These agents are recommended as part of first-line therapy in addition to maximally tolerated RAS blockade and lifestyle interventions. Importantly, the guidelines highlight that the benefits of SGLT2 inhibitors are not limited to glycemic control but are largely attributable to their cardiorenal protective effects. Accordingly, SGLT2 inhibitors can be added to existing glucose-lowering therapies regardless of baseline glycemic status. A modest and reversible decline in eGFR following treatment initiation is commonly observed and should not prompt discontinuation in the absence of other clinical concerns. Once initiated, continuation of SGLT2 inhibitors is generally recommended even if eGFR declines <20 mL/min/1.73 m2 unless the therapy is not tolerated or kidney replacement therapy is initiated. Temporary discontinuation should be considered during acute illness, surgery, or conditions associated with volume depletion or ketosis risk [40].
Accordingly, the American Diabetes Association 2026 guidelines support the use of SGLT2 inhibitors in patients with T2D and CKD to reduce the risk of disease progression and cardiovascular events [41]. The recently published Korean Society of Nephrology guideline also recommends SGLT2 inhibitors as standard therapy for patients with DKD, consistent with the KDIGO and ADA recommendations [42]. These recommendations reflect robust evidence demonstrating kidney and cardiovascular benefits in large RCTs. The incorporation of SGLT2 inhibitors into major clinical guidelines has led to a paradigm shift in DKD management, positioning these agents as cornerstone therapies for CKD patient management.
Use in special populations
Elderly patients represent a growing proportion of DKD cases [43]. Although concerns regarding volume depletion and hypotension exist, clinical trials and real-world studies suggest that SGLT2 inhibitors are generally well-tolerated in older adults when appropriately monitored [44,45]. Real-world data suggest that renal outcomes may vary depending on frailty-related factors, with increased risk of eGFR decline in elderly CKD patients with malnutrition, anemia, and proteinuria [46].
Non-albuminuric DKD is increasingly being recognized as a distinct phenotype of DKD [47]. Although early trials primarily enrolled patients with albuminuria, subsequent evidence has demonstrated that the benefits of SGLT2 inhibitors extend beyond this population. In the EMPA-KIDNEY trial, consistent kidney-protective effects were observed across a broad range of albuminuria levels, including in patients with minimal or no albuminuria [28]. Evidence from meta-analyses of cardiovascular and kidney outcome trials indicates that SGLT2 inhibitors are associated with a lower risk of kidney failure outcomes, regardless of baseline albuminuria. These findings support the potential role of early intervention, even before the development of overt DKD [48]. Although the magnitude of this effect may be attenuated at lower eGFR, these benefits appear to persist across a wide range of kidney functions. While randomized evidence in patients with eGFR <20 mL/min/1.73 m2 remains limited, observational studies suggest potential benefits even in stage 5 CKD, although these findings should be interpreted with caution [49,50].
Evidence for the use of SGLT2 inhibitors in kidney transplant recipients remains limited, as these patients were excluded from major RCTs. However, recent evidence from a systematic review and meta-analysis suggests that SGLT2 inhibitors are associated with improved clinical outcomes in this population. In pooled analyses of observational studies, SGLT2 inhibitor use was associated with reduced mortality and lower risks of cardiovascular and kidney events while maintaining stable kidney function. Additionally, these agents demonstrate favorable metabolic effects, including reduction in body weight and hemoglobin A1c levels, without an increased risk of infection [51]. Despite these promising findings, the evidence is largely based on observational studies with inherent limitations, underscoring the need for careful patient selection and further RCTs to confirm efficacy and safety in kidney transplant recipients. Consistent with this, the KDIGO 2022 guidelines do not currently recommend the routine use of SGLT2 inhibitors in kidney transplant recipients because of insufficient evidence [40].
In patients with type 1 diabetes, the use of SGLT2 inhibitors remains limited due to safety concerns, particularly the increased risk of diabetic ketoacidosis (DKA). Nevertheless, emerging evidence suggests potential kidney-related benefits. In post hoc analyses of the DEPICT-1 and DEPICT-2 trials conducted in adults, dapagliflozin was associated with modest reductions in albuminuria, particularly in patients with baseline albuminuria [52,53]. In the DEPICT program, dapagliflozin (5 mg and 10 mg) was associated with a numerically increased risk of DKA, with a more consistent and dose-dependent signal observed at the 10 mg dose and in DEPICT-2. In addition, the ATTEMPT trial in youth demonstrated that dapagliflozin reduced measured GFR, suggesting attenuation of glomerular hyperfiltration, with a favorable safety profile under structured risk mitigation strategies [54]. These findings raise the possibility of cardiorenal protective effects similar to those observed in T2D, although current evidence is limited to surrogate outcomes and short-term studies, with no data on hard kidney endpoints. Therefore, while routine use cannot be recommended, SGLT2 inhibitors may be considered with caution in carefully selected patients under close monitoring and appropriate risk mitigation strategies.
Safety considerations
SGLT2 inhibitors are generally well-tolerated; however, clinicians should remain aware of several important adverse effects and practical considerations. Although rare, euglycemic DKA may occur, particularly during prolonged fasting, acute illness, perioperative periods, or conditions associated with relative insulin deficiency. Current KDIGO guidance recommends temporary discontinuation of SGLT2 inhibitors during prolonged fasting, major surgery, or critical medical illness to reduce the risk of ketosis. For procedures requiring hospitalization or bowel preparation, SGLT2 inhibitors should generally be withheld at least 2 days before the procedure and restarted only after the patient has resumed normal oral intake and is clinically stable. In contrast, for minor day-stay procedures, withholding the medication on the day of the procedure is usually considered sufficient [40,55]. Volume depletion related to osmotic diuresis may occur, particularly in older adults or in patients receiving concomitant diuretics. Careful assessment of volume status and blood pressure is therefore recommended when initiating therapy, and adjustment of diuretic doses may be considered in high-risk individuals [56].
Genital mycotic infections are the most commonly reported adverse events and are typically mild and manageable with standard antifungal therapy. Patients should be educated regarding genital hygiene and early symptom recognition. Concerns regarding urinary tract infections (UTIs) have also been raised. Current evidence suggests that uncomplicated UTIs are usually manageable with standard antimicrobial therapy and do not routinely require discontinuation of SGLT2 inhibitors. Continuation of therapy is generally appropriate when infections are mild and respond promptly to treatment, given the substantial cardiovascular and kidney-protective benefits of these agents. However, temporary interruption or discontinuation should be considered in patients with recurrent or severe UTIs, pyelonephritis, urosepsis, or systemic illness requiring hospitalization [57].
Future directions
The therapeutic landscape for CKD continues to evolve rapidly. Although SGLT2 inhibitors have demonstrated consistent benefits across a broad range of patients, important knowledge gaps remain. As highlighted by the distribution of current evidence across the CKD heat map, several patient populations remain underrepresented in major clinical trials, including those with preserved kidney function and low levels of albuminuria, as well as those with advanced kidney failure (Fig. 3) [58]. Future clinical trials should prioritize these understudied populations to better define the role of SGLT2 inhibitors across the entire CKD spectrum. Further investigations are needed to clarify the mechanistic basis of kidney protection in different CKD phenotypes, including the relative contributions of hemodynamic, metabolic, inflammatory, and fibrotic pathways. Moreover, as combination therapy has emerged as a key strategy for DKD management, robust RCTs are required to establish the additive or synergistic effects of SGLT2 inhibitors in combination with other cardiorenal protective agents. Such studies are essential to optimize treatment strategies and support a transition toward mechanism-based, phenotype-driven, and individualized therapy for DKD.
Distribution of evidence and gaps in SGLT2 inhibitor trials across the CKD heat map.
This figure illustrates the distribution of major randomized clinical trials (RCTs) of SGLT2 inhibitors across the CKD spectrum defined by estimated glomerular filtration rate (eGFR) and albuminuria categories based on the Kidney Disease: Improving Global Outcomes (KDIGO) classification [58]. Colored boxes indicate the approximate inclusion criteria for key trials, including CREDENCE, DAPA-CKD, and EMPA-KIDNEY, mapped according to their respective eGFR and urine albumin-to-creatinine ratio (UACR) ranges. These trials predominantly enrolled patients with moderate to severe albuminuria (A2–A3), with a limited representation of patients with normal or mildly increased albuminuria (A1).
CKD, chronic kidney disease; SGLT2, sodium-glucose cotransporter 2.
Conclusion
SGLT2 inhibitors have emerged as foundational therapies for DKD patients. Large RCTs have consistently demonstrated that these agents reduce the risk of kidney disease progression, cardiovascular events, and hospitalization for heart failure. SGLT2 inhibitors exert renoprotective effects via multiple complementary pathways, including the restoration of tubuloglomerular feedback, attenuation of intraglomerular pressure, and suppression of inflammatory signaling. These benefits extend beyond glucose-lowering and are observed across a broad range of CKD populations. As evidence continues to accumulate, SGLT2 inhibitors have become the cornerstone of modern DKD patient management. Future research focusing on combination therapies and individualized treatment strategies may further improve outcomes in patients with DKD.
Notes
Conflicts of interest
All authors have no conflicts of interest to declare.
Funding
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. RS-2024-00342574).
Data sharing statement
The data presented in this study are available from the corresponding author upon reasonable request.
Authors’ contributions
Conceptualization: SHS
Funding acquisition: DWK
Methodology: All authors
Writing–original draft: All authors
Writing–review & editing: All authors
All authors read and approved the final manuscript.
